HS Code:
Ethchlorvynol (INN) is a sedative and hypnotic drug classified under the Harmonized System (HS) Code 2933.59, which generally pertains to heterocyclic compounds with nitrogen hetero-atom(s) only. It is primarily used in the treatment of insomnia and other sleep disorders. Due to its potential for dependency and abuse, its production and trade are strictly regulated in many countries. The global trade of Ethchlorvynol and related compounds is relatively niche, often involving pharmaceutical companies and specialized medical suppliers. Trade patterns are influenced by stringent regulatory frameworks, including international drug control treaties such as the UN Convention on Psychotropic Substances.
Total Trade Volume
USD 5.2 million
Data from 2022
Source
United Nations Comtrade Database
Average Rate
6.5%
Highest Rate
12% (imposed by certain developing countries)
Lowest Rate
0% (under free trade agreements or for medical use exemptions)
Declining demand due to newer alternatives
Reduced trade volumes as newer sedatives with lower dependency risks gain market share.
2020-2022
Increased regulatory scrutiny
Stricter controls have led to reduced legal trade and increased black market activity in some regions.
2019-2022
Shift to generic production
Lower costs due to patent expiration, driving trade growth in developing markets like India.
2018-2022
The World Health Organization updated its guidelines, recommending stricter controls on Ethchlorvynol due to abuse potential.
March 2023
Expected to reduce legal trade volumes as countries align with WHO recommendations.
The US Drug Enforcement Administration proposed reclassifying Ethchlorvynol under a more restrictive schedule.
July 2022
Likely to decrease imports into the US, redirecting trade to other regions.
The European Union implemented harmonized regulations for the trade of psychotropic drugs, including Ethchlorvynol.
January 2023
Streamlined trade within the EU but increased compliance costs for exporters.